The functional selectivity of adrenergic ligands for activation of β1-and β2-AR (adrenoceptor) subtypes has been extensively studied in cAMP signalling. Much less is known about ligand selectivity for arrestin-mediated signalling pathways. In the present study we used resonance energy transfer methods to compare the ability of β1-and β2-ARs to form a complex with the G-protein β-subunit or β-arrestin-2 in response to a variety of agonists with various degrees of efficacy. The profiles of β1-/β2-AR selectivity of the ligands for the two receptor-transducer interactions were sharply different. For G-protein coupling, the majority of ligands were more effective in activating the β2-AR, whereas for arrestin coupling the relationship was reversed. These data indicate that the β1-AR interacts more efficiently than β2-AR with arrestin, but less efficiently than β2-AR with G-protein.
INTRODUCTION
Although β 1 -and β 2 -AR (adrenoceptor) subtypes are structurally alike [1, 2] and interact similarly with the G-protein G s , which controls adenylate cyclase activity and cAMP-mediated signalling, many studies show that there are marked differences among subtypes in activating downstream signalling cascades [3] and eliciting functional responses [4] [5] [6] .
One element underlying the functional diversity between β 1 -and β 2 -AR subtypes is the different topology of membrane location and cAMP signalling patterns that these two proteins display when co-existing on the surface of the same adult myocardiocyte [7] . Selective compartmentalization into specialized membrane microdomains [8, 9] and the differential interaction of the C-termini of the receptors with PDZ-domaincontaining proteins [10] [11] [12] may be key factors that determine such location-dependent differences in signalling properties of the receptors.
However, there is also evidence that the interactions of β-AR subtypes with distinct signal transducers, such as G s , G i and β-arrestins, may differ, thus generating signalling diversity. Striking differences among the three β-AR subtypes were reported for the interaction with arrestins. It has been observed that the β 3 -AR subtype does not interact with arrestin [13] , nor undergoes GRK [GPCR (G-protein coupled receptor) kinase]-mediated phosphorylation in response to agonist occupation [14] , whereas the β 1 -AR was found to be less efficient than the β 2 -AR in interacting with arrestin [15] .
Arrestins were originally considered to be molecular devices specifically designed to 'arrest' G-protein-receptor signalling. It is now clear, however, that these proteins, particularly β-arrestin-1 and -2, are fully fledged signal transducers [16, 17] , and the broadness of the signalling network they can regulate has been recently exposed by comprehensive phosphoproteomic analysis [18, 19] .
Several studies have focused on agonists that, acting on the same receptor subtype, can display differential efficacy for the interaction with the alternative tranducers G-protein and arrestin [17] . This transducer-dependent difference in agonist efficacy, commonly called biased agonism or ligand-directed signalling [3, 20, 21] , has been investigated for the β 2 -AR subtype, where a number of agonists with a slight preference for arrestin interactions were reported [22, 23] . However, an evaluation of how ligands differentially activate β 1 -AR and β 2 -AR in promoting Gprotein or arrestin interactions is not available.
In the present study we used RET (resonance energy transfer) to compare the differential ability of the two AR subtypes to form a complex with each transducer in response to occupation by 45 distinct adrenergic structures. The results of the present study show that the β 1 -AR/β 2 -AR selectivity of adrenergics is strikingly different between arrestin and G-protein interactions.
previously isolated from embryos carrying the targeted ablation of Gnas exon 2 [24] was made available to us by Dr M. Bastepe (Harvard Medical School, Boston, MA, U.S.A.) and Dr O.H. Onaran (Ankara University, Ankara, Turkey). Adrenergic ligands were purchased from Bachem or Tocris, or were kindly donated by Dr Ad Ijzermann (University of Leiden, Leiden, The Netherlands). Details on source, structures and abbreviations for the ligands used in this paper are listed in Supplementary Table S1 (at http://www.BiochemJ.org/bj/438/bj4380191add.htm)
Plasmid constructs
β1-AR and β2-AR fused to Rluc (Renilla luciferase) were obtained by inserting the PCR fragments encoding each receptor cDNA into the Renilla Luciferase Vector (Packard), upstream of the Rluc-coding sequence. The resulting β1-AR-Rluc and β2-AR-Rluc chimaeras were then transferred into neomycinresistance retroviral expression vectors (pQC series, Clontech).
RGFP (Renilla green fluorescent protein)-tagged transducers were made by linking the amplified RGFP-coding sequence (from Prolume) to the second codon of either the bovine β 1 subunit of the heterotrimeric G-protein (G β1 ), through a 21-mer linker peptide (EEQKLISEEDLGILDGGSGSG), or to the β-arrestin-2 cDNA sequence, through a 13-mer peptide corresponding to the c-Myc epitope (EEQKLISEEDLGRT). Both constructs were transferred into hygromicin-resistant retroviral vectors (pQH), which were used to generate the viral supernatants used for cell transduction. Retroviral vectors expressing the long form of the human G α protein G αsL were obtained by transferring the G αsL -coding sequence from the pcDNA3.1 plasmid (Missouri S&T cDNA Resource Centre) to the retroviral vector pQP bearing the puromycin-resistant gene coding sequence. We also prepared a luminescent β-arrestin-2 chimaera using a similar procedure. Rluc cDNA was fused to the β-arrestin-2-coding sequence using a 21-mer linker peptide (GDLGELSREEQKLISEEDLRT), and subcloned into a neomycin-resistant retroviral vector. This construct was used to prepare cells co-expressing luminescent arrestin and a membrane-targeted variant of RGFP, which carries at the C-terminus the farnesylation-palmitoylation consensus sequence of hRAS [25] .
Cell lines
HEK (human embryonic kidney)-293 cell lines were cultured in DMEM (Dulbecco's modified Eagle's medium) and 2B2 cell lines in a 50 % mixture of DMEM and F12, both media containing 10 % FBS. Cell lines stably co-expressing each luminescent AR in association with either RGFP-tagged G β1 or RGFP-β-arrestin-2 transducers were obtained by infecting cells sequentially with retroviruses encoding the single fusion proteins followed by selection with G418 (500 μg/ml) in combination with hygromicin B (100 μg/ml). 2B2 cell lines additionally expressing exogenous G αsL were also obtained by viral transduction and puromycin selection. Clones expressing different ratios of chimaeric proteins were isolated after low-density plating of virally transduced cells, and 2-3 weeks of culture in the presence of the proper antibiotics.
Expression levels of luminescent and fluorescent chimaeric proteins
To measure the receptor density of chimaeric receptors we used ( − )-[ 125 I]pindolol (Amersham). Cell monolayers were detached using Ca 2 + /Mg 2 + -free PBS (PBS − ) containing 1 mM EDTA, and pelleted at 600 g. After resuspension in PBS − , duplicate aliquots of ∼100 000 cells were incubated with the radioligand (10 pM) with or without 12 log-spaced concentrations of unlabelled pindolol in a total volume of 1 ml. The reaction was carried out for 90 min at 20
• C, and terminated by rapid filtration on to GF/B glass fibre microplates (Filtermate 196, Packard) . Radioactivity was counted and binding constants computed as described previously [26] . The B max (fmol/μg of proteins + − S.E.M., n = 3) measured in the main cell lines used in the present study were as follows. In 2B2 cells co-expressing RGFP-β-arrestin-2 the B max for β 2 -AR was 1.43 ( + − 0.2) and for β 1 -AR was 1.22 ( + − 0.12). In HEK-293 cells co-expressing RGFP-G β1 the B max for β 2 -AR was 2.6 ( + − 0.73) and for β 1 -AR was 5.3 ( + − 0.85). The K d values (in pM + − S.E.M., n = 6) for pindolol were 386 ( + − 77) at β 2 -AR and 918 ( + − 138) at β 1 -AR.
Further characterization of the level of fusion proteins and their ratios in the cell lines and additional clones generated in the present study was performed by measuring the intrinsic luminescence and fluorescence of cell-membrane preparations or whole-cell extracts, according to transducer localization, as reported previously [25] . Enriched plasma membranes were prepared as described in [26] .
Cholera-toxin-catalysed ADP-ribosylation
Cholera toxin labelling of α-subunits was performed using 100 μg of membrane proteins prepared from 2B2-KO (knockout)-and 2B2-G αs -reconstituted cells as described previously [26] . Proteins were then separated by SDS/PAGE. The radioactivity of the bands corresponding to G α subunits was quantified on a vacuumdried gel with a microchannel array detector counter (Packard Instant Imager). To ADP-ribosylate endogenous subunits, cell monolayers were exposed to pertussis toxin (50 ng/ml) for 18 h prior to harvesting.
BRET (bioluminescence RET) recording of receptor-transducer interactions
The use of Renilla photoproteins as reporters of protein-protein interactions has been described previously [27] . Luminescence was recorded using 96-well white plates (Packard View Plate) using a plate luminometer (VICTOR light, PerkinElmer) equipped with two independent automatic injectors.
G-protein-coupling assays were performed on membranes prepared from HEK-293 or 2B2 cells expressing each luminescent receptor plus RGFP-G β1 ; membranes were incubated in PBS containing 2.5 μM coelenterazine for 10 min. Aliquots (5 μg/75 μl) of suspension were rapidly distributed into a white 96-well OptiPlate (PerkinElmer) already preloaded with 25 μl of PBS containing or not adrenergic ligands at 4-fold the final desired concentration. The plate was counted in the luminometer after 3 min of further incubation. Receptor-arrestin interactions were measured on monolayers of intact 2B2 cells. After overnight growth in 96-well OptiPlates, cell culture medium was replaced with 90 μl of PBS containing 2.5 μM bDOC, and incubated for 2 min prior to the addition of 10 μl of serial dilutions of the ligands (10-fold the final concentration in PBS), which had been prepared in a companion plate. Luminescence was recorded after an additional 10 min of incubation. Maximal effects for all ligands were determined using a single saturating concentration (10-100 μM). In addition, agonists displaying a significant effect in at least one of the four assays were further characterized by construction of concentration-response curves, using seven or 11 half-log-spaced concentrations of each ligand in duplicate wells. In both types of assays, adrenaline (epinephrine) was used as the reference ligand and included in every test plate to account for inter-assay variability of the estimated parameters.
Kinetic experiments were performed as described previously [25] .
The direct effect of adrenergics on the luciferase activity of Rluc was measured as described previously [25] . Since several compounds had significant inhibitory activity (20-40 %) on the enzyme at 1 mM, concentrations greater than 100 μM were avoided in the determination of BRET ratios. Consequently, for a few ligands (e.g. dopamine, its N-methyl analogue MAPE, and sulfonterol) the concentration-response curves in some assays did not reach a true experimentally determined plateau level. In such cases, the E max value was extrapolated through the fitting routine (see below), by constraining the a parameter of the curve to be equal to or less than that for adrenaline. Because such parameter estimates are not obtained with the same degree of experimental confidence as the others, they were not included in the final comparison of intrinsic activities (Figures 6B and 6C) and are marked by asterisks in the final Tables.
Data analysis
RET ratios were determined as the ratios of high energy (donor) and low energy (acceptor) emissions, sequentially recorded with different filters [25] . Using coelenterazine, light was recorded through 450/20 nm and 510/20 nm windows, and RET ratios, corrected for spectral overlap, are calculated as:
where T is the maximal transmittance in the two filter sets. With bDOC light was recorded through short-pass (450 nm cut-off) and long-pass (490 nm cut-off) filters and the RET ratio (bDOC) = cps LP /cps SP (LP is long-pass and SP is short-pass).
The relative E max of all ligands (intrinsic activities) were computed as the fraction of the E max for adrenaline, after subtraction of the RET signal recorded in the absence of ligand. Concentrationresponse curves were analysed by non-linear curve fitting to the general logistic function:
where y and x are the RET ratio and ligand concentration, a and d are upper and lower asymptotes, c is the ligand concentration yielding half-maximal RET change, and b is the slope factor at c. From best-fitting parameters, the EC 50 (c) and E max (a − d) of each ligand were obtained. The significance of the difference of fitted parameters among ligands were assessed according to the extra sum of squares principle [28] . Agonist-induced changes of RET kinetics were fitted to an exponential change function:
where, t is the time difference (s) from ligand injection, Y 0 is the baseline RET signal, and Y i and τ i are amplitude and time constant (s) of n exponential components.
RESULTS

RET analysis of receptor-G β subunit interaction in membranes and the role of G α subunits
Receptor-G-protein efficacy was measured using a previously described cell-free BRET assay [25] , to eliminate the inhibitory effect of endogenous arrestins on the receptor-G-protein interaction. We used membranes from HEK-293 cells coexpressing either β 2 -AR -Rluc or β 1 -AR-Rluc and RGFP-G β1 . The agonist-induced interaction between receptor and the β 1 subunit of heterotrimeric G-proteins (G β1 ) in membranes results in enhancement of the RET signal, denoting a diminution of distance between the C-terminus of the receptor and the G β1 N-terminus. As discussed previously [25] , it is not possible to discriminate whether such a change is due to the rearrangement of a pre-associated supramolecular complex or to micro-association reactions among proteins that diffuse along the plane of the membrane (and may perhaps be confined within specialized microdomains).
The interaction kinetics of β-ARs was similar to that previously observed for opioid receptors (t 1/2 , 10-15 s), reaching a plateau within 1 min from agonist addition, with no apparent differences between β 2 -and β 1 -AR subtypes (results not shown). The rank order of the potency of catecholamine for RET enhancement (isoproterenol adrenaline noradrenaline in β 2 -AR compared with isoproterenol > noradrenaline adrenaline in β 1 -AR) follows the typical pattern established in physiological studies ( Figures 1A and 1B) . Both agonist effect and block by antagonist displayed the distinctive enantioselectivity expected for β 2 -AR ( Figures 1C and 1D ). Thus the receptor-G-protein interaction described by the resonance signal appears to maintain the characteristics of native ARs, despite the presence of fused reporter tags on both partners.
As previously observed for opioids [25] , this signal results from a trimolecular interaction that requires G α subunits. To investigate which G α subunits are involved, we used a MEF (mouse embryonic fibroblast) cell line (2B2) established from transgenic mouse embryos that carry a targeted deletion of the G αs gene [24] . Several lines co-expressing β 1 -AR-Rluc or β 2 -AR-Rluc and RGFP-G β1 were engineered. In addition, we reintroduced a functional 'dark' G αs subunit in this host, by transducing β 2 -AR/G β1 -2B2 cells with a retroviral vector coding for the 'long' spliced-variant form of the GNAS gene (G αsL ).
Activation of the β 2 -AR was compared in membranes from 2B2 and 2B2-G αs cells, both of which were treated or not with pertussis toxin overnight. Agonist-induced enhancement of RET was reduced by 80 % in membranes of cells lacking the G αs subunits, but a smaller signal still persisted. Pertussis toxin treatment abolished the agonist response in cells lacking the G αs subunit, but produced only slight inhibition (∼20 %) in the presence of G αs (Figures 2A and 2B ). Similar pertussistoxin-sensitive signals were observed in 2B2 cells expressing β 1 -AR (results not shown). These results indicate that although G αs accounts for the majority of the interaction reported by the resonance signal, a smaller interaction supported by pertussissensitive G αi protein exists in both receptor subtypes.
To confirm this suggestion, we measured direct interactions of β 2 -AR-Rluc with endogenous α-subunits using agonist-induced enhancement of cholera-toxin-catalysed ADP-ribosylation in the same 2B2 and 2B2-G αs membranes. In the absence of G αs , isoproterenol enhanced [ 32 P]ADP-ribose incorporation into the 40 kDa band corresponding to G αi , and the effect was inhibited by the β-blocker ICI-118551. In membranes reconstituted with G αs , the agonist primarily increased the labelling of a 46/48 kDa doublet corresponding to G αsL , but no clear effect on G αi labelling was detected in this case, suggesting that in the presence of G αs the interaction with G αi may be negligible ( Figure 2C ). The agonistinduced enhancement of cholera toxin labelling of the 40 kDa band in 2B2 membranes was abolished following treatment of the cells with pertussis toxin (50 ng/ml, 18 h), suggesting that the labelled protein is a member of the G i/o family of G-proteins (results not shown). Such results also indicate that the ability of the luciferase-fused receptor to interact with endogenous α-subunits in the membrane is preserved. As observed in the opioid receptor system, the adrenergic RET signal was rapidly suppressed by guanine nucleotides. We used this allosteric signal-quenching reaction to compare the relative potency of GDP to inhibit adrenaline-induced interactions at the two receptor subtypes. The IC 50 for GDP was 10-fold lower at the β 1 receptor than at the β 2 receptor (Figure 3) , suggesting that the β 2 -AR subtype can form a much more stable complex with G αβγ than the β 1 -AR, despite the similarity in interaction kinetics.
Receptor-arrestin interaction: kinetics and role of G α subunits Our objective was to determine the intrinsic activity of agonists for each AR-arrestin coupling without the influence of the concurrent receptor-G-protein interaction. Thus 2B2 G αs -KO cells coexpressing each luminescent receptor type and fluorescent β-arrestin-2 were prepared. In addition, β 2 -AR-arrestin coexpressing cells were also transduced with dark G αsL , to evaluate if, and to what extent, the presence of G αs might modify the interactions.
Both β 1 -AR and β 2 -AR interact rapidly with arrestin, approaching steady-state within 5 min following agonist injection to the cell monolayer. However, the initial rate of the β 2 -AR subtype is somewhat delayed by a slower transient of RET increase in the first 30 s (Figure 4 ). Modelled by monoexponential functions, the t 1/2 of the adrenaline-induced β 1 -AR-arrestin interaction was smaller (35 + − 7 s) than that of β 2 -AR-arrestin (76 + − 9 s). Partial agonists displayed reduced maximal effects with slower rates in both β 1 -AR and β 2 -AR ( Figures 4A and 4B) , whereas lowering the molar concentration of agonist primarily reduced amplitudes, and not rates, for concentrations >30 nM ( Figure 4C ). 
were assayed for RET in the presence of 10 μM adrenaline (EPI) and increasing concentrations of GDP (x axis). Data are averaged from two separate experiments and are expressed as a fraction of the effect measured in the absence of nucleotide. (B) Membranes were prepared from two cell clones expressing different levels of β 2 -AR-Rluc and RGFP-G β1 and the effect of GDP was measured as described in (A). Data are means of triplicate determinations in a single experiment. To test for a difference of IC 50 in the two clones, data were first fitted with no constraints, and then refitted by forcing a common parameter c. The second fit was not significantly worse (P = 0.37) as determined by extra-sum-of-square statistics [28] , indicating that the IC 50 of GDP is similar in the two curves. Thus GDP potency does not depend on the magnitude of RET signal measured in the two membranes. We also found that for β 1 -AR RET kinetics, a two-component exponential model (with t 1/2 ranging from 3 to 7 s and from 30 to 100 s) often afforded significant reductions of the fit standard error. This is similar to the biphasic kinetics described previously for the β 2 -AR-β-arrestin-2 interaction in single-cell imaging FRET studies [29] . However, we failed to find a consistent relationship between agonist efficacy and t 1/2 or amplitudes of the two components. For β 2 -AR kinetics, the s-shaped inflection in the initial time course prevented significant improvements by fitting a sum of exponentials, unless two components with amplitudes of opposite sign were allowed in the model. Although improving fitting statistics, the physical interpretation of such a model is unclear. For this reason and because estimating both amplitudes and rates from multi-exponential fits of experimental data is a notorious ill-posed problem [30] , all comparisons of kinetic parameters in the present study are based on monoexponential approximations of the data.
Regardless of the complexity, the data in Figure 4 indicate that the maximal enhancement of RET at steady-state is a good descriptor of ligand efficacy for both β 1 -and β 2 -AR subtypes. Thus this parameter was chosen to assess ligand intrinsic activities for receptor-arrestin coupling in subsequent studies.
As observed for the G-proteins, concentration-response curves of catecholamines for arrestin coupling displayed the typical signature of β 1 -/β 2 -AR pharmacology (catecholamine potencies and agonist stereoselectivity are in Figure 5 ). Interestingly, the EC 50 of the three catecholamines for β 1 -AR were smaller at arrestin than at G-protein, whereas this trend was reversed for β 2 -AR (see Table 2 and Supplementary Table S1 ).
To verify that the C-terminal Rluc extension of ARs does not modify the intrinsic ability of the receptor to interact with arrestin, we also developed an indirect BRET system capable of detecting arrestin binding to intact wild-type receptors for the β 2 -AR subtype. We took advantage of an mtRGFP (membranetargeted RGFP) variant previously used to monitor receptor internalization [25] . This protein is localized in close proximity to luminescent receptors thus producing a high RET signal, which fades away as agonist binding triggers receptor endocytosis. Exploiting the same principle, we could detect the docking of luminescent arrestin to 'dark' wild-type β 2 -AR through the increase of proximity-induced RET between the arrestin-tethered Rluc donor and the membrane-anchored RGFP acceptor. In HEK-293 cells co-expressing mtRGFP plus Rluc-β-arrestin-2, and further transduced with wild-type β 2 -AR, the intrinsic activity of agonists was in good agreement with that measured using the conventional assay in 2B2 cells (Supplementary Figure S1 at http://www.BiochemJ.org/bj/438/bj4380191add.htm), indicating that Rluc tagging does not change receptor efficacy for arrestin. The agreement between the two assays also suggests that the bulk of BRET signal that we measure in the present study is generated by an arrestin-receptor complex present on the cell surface rather than segregated into endocytic vesicles. In fact, unlike the direct interaction between luminescent receptor and fluorescent arrestin, the indirect RET between receptor-bound luminescent arrestin and membrane-anchored RGFP is interrupted as the receptorarrestin complex undergoes endocytosis [25] .
The role of G αs on the receptor-arrestin interaction was evaluated by comparing the relative E max of a series of adrenergic agonists in β 2 -AR-β-arrestin-2 cells expressing or not the cotransfected G αsL gene. The correlation between the intrinsic activities of ligands measured in the two cell lines was tight (Supplementary Figure S2 at http://www.BiochemJ.org/ bj/438/bj4380191add.htm), indicating that the coupling with G α subunits does not manifestly change the efficiency of ligands in inducing receptor-arrestin interaction. Similarly, there was no influence of functional G αi subunits when agonist intrinsic activities for β 2 -AR or β 1 -AR were compared in cells that had been exposed or not to pertussis toxin (results not shown), nor did pertussis toxin significantly alter the kinetics of the RET signal triggered by full agonists in β 2 -AR-β-arrestin-2 or in β 1 -AR-β-arrestin-2 cells ( Figure 4D ).
Thus, taken together, these results show that the receptor-G-protein interaction does not appear to modify the binding of receptor to arrestin reported by RET, neither directly via proteinprotein associations, nor indirectly via activation of signalling pathways.
Effect of apparent receptor-transducer stoichiometry on intrinsic activity
To investigate how the relative E max of ligands may depend on the level of expression of receptor-G β -interacting partners for each receptor subtype, we selected clones with a different stoichiometry of the two chimaeric proteins, as determined by the luminescence and fluorescence of the tethered reporters. The stoichiometry of expression had no detectable effect on the relative intrinsic activity of agonists for both receptor subtypes (Supplementary Figure S3 at http://www.BiochemJ.org/bj/ 438/bj4380191add.htm). Interestingly, however, the overexpression of 'dark' G αs subunit significantly increased the intrinsic activity of the partial agonist clenbuterol for the β 2 -AR (Supplementary Figure S3D) . The cell lines used in the present study had comparable levels of G αs expression in immunoblots (results not shown). Nonetheless the final results were collected using at least two different clones for each receptor subtype to minimize the chance that unknown differences in endogenous G-protein subunits could bias the final results.
For the study of arrestin coupling we could not obtain lines showing a significant variation in the expression of fluorescent arrestin. Thus cell lines expressing equal levels of luminescent β 2 -ARs or β 1 -ARs and fluorescently labelled arrestin were selected and used for pharmacological analysis. However, to evaluate how a change of expression stoichiometry could affect the results, we generated a cell line expressing a 2.5-fold higher level of β 2 -AR luminescence, with no difference in fluorescence expression. The raised receptor/arrestin ratio in cells expressing a higher level of receptor slightly increased the intrinsic activity of a number of partial agonists (Supplementary Figure  S4 at http://www.BiochemJ.org/bj/438/bj4380191add.htm). This indicates that in the β 2 -AR and β 1 -AR cell lines used for the comparison, the receptor/arrestin ratio is safely below the critical 1:1 proportion, where even small differences (easily masked by experimental noise in the determination of intrinsic luminescence and fluorescence) might affect the comparison of relative E max of ligands across receptors. (More discussion on this point is in the Supplementary Material section entitled "Analysis of ligand-induced receptor activation using RET methods" at http://www.BiochemJ.org/bj/438/bj4380191add. htm). (A) The shift of intrinsic activity (y axis) was computed as the net difference between β 1 -AR and β 2 -AR intrinsic activities measured for G-protein coupling (grey) and arrestin coupling (black) using the cumulative data shown in Table 1 . Error bars were calculated from the sum-of-variances of the data. Positive numbers indicate the net β 1 -AR preference and negative numbers indicate the β 2 -AR preference. Data are shown in histogram form, sorted according to decreasing net difference. Asterisks mark ligands for which plateau E max values could not be reached with the highest concentration, in at least one of the four assays (see the Experimental section). Ligand abbreviations are as listed in Supplementary Table S1 (at http://www.BiochemJ.org/bj/438/bj4380191add.htm). (B and C) β 1 -AR intrinsic activities plotted as a function of β 2 -AR intrinsic activities for arrestin-(B) and G-protein-(C) coupling assays. Data are ordered according to increasing β 2 -AR effects. Broken lines are the line of identity, whereas the solid lines were traced using a polynomial function to approximate the general trend of the data points. Ligands marked with arrows (grey triangles) showing most evident variations from the general trend are discussed in the text. (D). The β 1 -AR and β 2 -AR-arrestin intrinsic activities of the group of ligands exhibiting highest β 1 -AR selectivity (arrows in B) are replotted with those of ligands having similar effects on both receptors. Note the reversal in rank ordering of efficacy. With respect to, for example, albuterol, the relative E max is progressively increasing at β1-AR, while concomitantly fading to undetectable levels at β 2 -AR. Using the BRET interaction assays described above, we compared the intrinsic activity of 45 adrenergic ligands, including antagonists and agonists endowed with various degrees of efficacy. The entire data set is available in Supplementary Table S1 . Mean intrinsic activity data pooled from both concentration-response curves and determinations at a single saturating concentration are also reported in Table 1 , while the EC 50 values are in Table 2 .
To mark the ligands exhibiting the largest β 1 -/β 2 -AR difference in maximal complex formed with each transducer we plotted the net difference between relative intrinsic activities (β-AR 1 minus β 2 -AR) of all ligands. This index arbitrarily sets β 1 -AR selectivity as positive and β 2 -AR selectivity as negative numbers ( Figure 6A) .
For receptor-G-protein interactions, cimeterol is the ligand with the highest level of β 2 -AR selectivity, followed by MAPE and N-methyl-dopamine (although E max values of the latter two ligands may be underestimated, given the very low potency for the β 1 -AR-G-protein interaction). Other structures with significant β 2 -AR preferential effects include well-known β 2 -AR agonists, such as albuterol, clenbuterol and terbutaline. A direct plot of Gprotein intrinsic activity for the two receptor subtypes ( Figure 6C ) shows an overall β 2 -AR preference in promoting G-protein coupling for the majority of ligands, but no marked reversal of the ordering of efficacy. Only CGP-12177 and xamoterol (β 2 -AR antagonist and partial agonist respectively) show significant β 1 -AR preference ( Figure 6C and Table 1 ). This preserved ranking of efficacy across β 1 and β 2 receptor subtypes for G-protein coupling largely agrees with a recent study based on cAMP signalling measurements [31] .
For the receptor-arrestin interaction, the trend is reversed. The direct comparison of intrinsic activity data shows an inverse pattern compared with G-protein ( Figure 6B ). Many ligands with β 2 -AR preference on G-protein show β 1 -AR preference on arrestin. Even two notorious β 2 -AR agonists, such as cimeterol or clenbuterol, gain a slightly greater β 1 -AR intrinsic activity in promoting receptor-arrestin interaction ( Figure 6A and Table 1) .
Such a switch towards β 1 -AR preference as the transducer shifts from G-protein to arrestin is also apparent on examination of the EC 50 values of ligands (Table 2 ). For G-protein coupling most ligands exhibit significantly smaller EC 50 values at the β 2 -AR subtype, but the ratio of potency in favour of β 2 -AR is drastically reduced for arrestin coupling (Table 2 and Supplementary Table  S1 ). Most impressive is the change for clenbuterol, with a 200-fold shift towards the β 1 -AR as we move from G-protein to arrestin. Also interesting is the potency of noradrenaline: the EC 50 ratio shows only a 2-fold β 1 -AR selectivity for G-protein coupling, but rises to 160-fold for the arrestin interaction ( Table 2 ).
Note that although carvedilol was reported to induce translocation of arrestin to the membrane via β 2 -AR [32, 33] , in the present study we only see a minor effect of carvedilol at β 1 -AR and none at β 2 -AR for arrestin coupling (Table 1) . It would be interesting to investigate whether this discrepancy only reflects a technical difference, or underlies an important functional separation between the biological events that are monitored by the two types of assay.
Table 1 Ligand intrinsic activities (E max minus basal as fraction of adrenaline values)
Weighted means from both single saturating concentration experiments and concentration-response curves (the latter were given double weight in the final mean calculation). 
Agonists with restricted β 1 -AR-arrestin efficacy
In addition to the global shift towards β 1 -AR observed for most structures, a number of agonists (particularly dobutamine, synephrine analogues, dopamine and ritodrine) exhibit a clear reversal in the relative order of β 2 -/β 1 -AR efficacy for arrestin. This is best illustrated in Figure 6(D) , where such ligands are compared with other agonists that maintain similar relative effects at both subtypes. In contrast with albuterol (which shows a similar E max in both subtypes), the maximal receptor-arrestin complex induced by such ligands decreases to negligible levels at β 2 -AR while concomitantly increasing at β 1 -AR ( Figure 6D ). The loss of β 2 -AR efficacy with high β 1 -AR efficacy for arrestin in such ligands suggests that they can act as competitive antagonists of β 2 -AR-arrestin interactions. This was further investigated using dobutamine.
The concentration-response curves shown in Figure 7 indicate that dobutamine is a strong partial agonist [IA (intrinsic activity) = 0.5-0.6 relative to adrenaline] for both the β 1 -ARand β 2 -AR-G-protein interactions, and even slightly stronger (IA = 0.75) for the β 1 -AR-arrestin interaction. In contrast, dobutamine produces no effect on the β 2 -AR-arrestin interaction. However, the concentration-response curves of adrenaline in the presence of increasing concentrations of dobutamine show a typical rightward shift of EC 50 indicating competitive antagonism ( Figure 7 ). The pA 2 constant computed from Schild plot analysis of such experiments (6.52 + − 0.3) is in good agreement with the EC 50 of dobutamine determined for the β 2 -AR-G-protein Table 2 Comparison of the potency of adrenergic ligands (expressed as a log10 molar value of the EC 50 ) for inducing β 2 -AR or β 1 -AR coupling to G-protein and arrestin
Only ligands for which a comparison can be made are presented here. The complete data set is given in Supplementary Table S1 (at http://www.BiochemJ.org/bj/438/bj4380191add.htm). Err, the range of values for n = 2 or S.E.M. for n > 2; No crc, the ligand effect was not sufficient to obtain a reliable concentration-response curve. Data extrapolated from computer fittings are labelled with asterisks as in Table 1 .
Receptor-G protein interaction
Receptor-arrestin interaction interaction ( − 6.85 + − 0.2) (see Table 2 ). Although dobutamine is a racemic mix of two enantiomers [34] , which were not tested in resolved form in the present study, the inability of racemic dobutamine to form a detectable β 2 -AR-arrestin complex suggests that both enantiomers have no efficacy on this interaction.
DISCUSSION
We have compared the ability of the structurally similar β 1 -ARs and β 2 -ARs to bind the major transduction proteins that mediate their biological effects, G-proteins and β-arrestin-2, in response to occupation by 45 different ligand structures. The interaction was quantified as maximal enhancement of RET ratio induced by each ligand (relative to the reference agonist adrenaline). This enhancement of RET ratio reflects two equiprobable mechanisms: (i) intramolecular rearrangement of a pre-existing complex that results in tighter receptor-transducer association or (ii) the formation of a new receptor-transducer complex. Any of the two mechanisms might be involved in G-protein coupling, whereas the second is most likely to be involved in arrestin coupling. In both reactions the 'molecular efficacy' of the ligand is given by the free-energy change that couples the binding sites of ligand and transducer on the receptor molecule [35] . This free-energy change and the maximal ratio transducerbound compared with unbound receptor (i.e. the E max in RET) are predicted to be linearly related according to the first mechanism, and are also virtually linear according to the second, unless the receptor exceeds the transducer concentration. However, theoretical analysis (given in-depth in the Supplementary Material section entitled "Analysis of ligand-induced receptor activation using RET methods") also shows that any deviation from 100 % RET efficiency of the reporter system introduces significant non-linearity between the optical signal and the molar fraction of transducer-bound receptor. Consequently, the differences of intrinsic activities between two receptor subtypes not only reflect divergences in ligand molecular efficacy, but also in the stoichiometry and the affinity/stability of transducer-receptor complexes.
For this reason, experiments were designed to assess how the stoichiometry between receptor and transducer can influence the observed differences. In the G-protein system, the intrinsic activity of the ligand was not affected by a wide range of receptor/G β1 expression ratios, except when the abundance of G αs was enhanced by overexpression. Such a result is consistent with the idea that in this system the change of RET reflects internal rearrangements of a preformed receptor-G αβγ complex [25] , although it cannot rule out alternative mechanisms. The effect of G αs overexpression may suggest that this subunit is the limiting factor in the stability of functional receptor-transducer complexes that can be preassembled in the membrane. In the arrestin system, we used cell lines with identical expression levels of luminescent receptors and fluorescent arrestin, to ensure that the results were independent of differences in relative expression. Doubling receptor expression of the β 2 subtype at equal arrestin levels shifted the E max of partial agonists only slightly, indicating that small differences of expression in the cell lines used for the analysis cannot affect the comparison.
Even if the role of expression stoichiometry can be discounted, changes of ligand E max between the two receptors reflect both a difference in ligand molecular efficacy and a difference in receptor-transducer affinity. The first involves particular ligands individually, the second affects all ligands, but to a variable extent according to their efficacy, because of the hyperbolic relationship between the fraction of transducer-receptor complex and the optical RET signal (Supplementary Material section entitled "Analysis of ligand-induced receptor activation using RET methods"). The exact distinction of 'individual' and 'global' differences is obviously impossible in the presence of experimental noise. However, the large panel of ligands examined in the present study helps to identify general trends resulting from a difference in transducer-receptor affinity, as such a difference alters the linearity, but not the ordering, of ligand efficacies. In contrast, individual ligand divergences that significantly change the ranking of intrinsic activities between receptor subtypes more probably reflect a true diversity in the conformational perturbations that the structure of the ligand can transmit on the two receptor molecules.
According to this interpretation algorithm, most of the β 1 -/β 2 -ARs in ligand intrinsic activities for G-protein coupling primarily reflect a molecular difference of G-protein interaction between the two receptors, rather than individual divergences of efficacy among ligands. When compared on the same plot ( Figure 6C ), the bulk of E max data deviates from the identity line and bends towards the β 2 -AR axis, with the largest differences occurring in the mid range (0.4-0.6) of intrinsic activity. This is the pattern expected if we assume that β 2 -AR can establish a more stable interaction than the β 1 -AR subtype with G-protein subunits. This conclusion agrees with our finding that the potency of GDP to quench adrenaline-induced coupling is 10-fold greater at β 1 -AR than at β 2 -AR. It also agrees with previous work where β 1 -/β 2 -AR subtype differences were assessed in conventional signalling assays [36] . Only a few ligands that appear to deviate significantly from this general trend (e.g. CGP12177 and xamoterol) are structures possibly endowed with the ability to induce a better G-protein-interacting conformation when occupying the β 1 -AR-, rather than the β 2 -AR-binding site.
In contrast, the mirror-like trend in the differences of ligand intrinsic activities observed for arrestin coupling ( Figure 6B) indicates that the default β 2 -AR preference existing for G-proteins is abolished or reversed for arrestin. This suggests that the β 1 subtype interacts with the arrestin/GRK system more efficiently than the β 2 -AR. Note that this inversion cannot be attributed to the stronger coupling of β 2 -AR to G αs (which thus may 'compete' against arrestin), because in the present study arrestin interactions were recorded under a G s -null background. A greater arrestin affinity and/or phosphorylation efficiency of the β 1 subtype may be responsible for this global shift. Although for arrestins there is no allosteric inhibitor of transducer-receptor interaction (like GDP) to support this finding, the faster kinetics observed for the β 1 -AR-arrestin interaction would be in-line with such a conclusion.
Our data seem to contrast with other studies that reported a reduced ability of β 1 -AR to undergo internalization and down-regulation compared with β 2 -AR [15, [37] [38] [39] . However, while in previous work the comparison was based on events downstream of the arrestin-receptor complex, in the present study we directly measured the formation of that complex. Moreover, the comparison of two alternative ways to measure the β 2 -ARarrestin interactions (Supplementary Figure S1) suggests that the arrestin-receptor complex responsible for the bulk of RET signal is probably on the cell surface. Thus it is possible that despite a stronger interaction with arrestin, the β 1 -AR-arrestin complex might be less efficient in progressing along the subsequent steps of endocytosis and recycling than the β 2 -AR. More experiments are necessary to clarify this surprising paradox.
Some agonists display levels of β 1 -AR efficacy for arrestin coupling which are greater than expected from the general trend. Besides xamoterol and CGP12177 (already displaying β 1 preference in G-protein coupling), the most obvious is a cluster of agonists (e.g. dobutamine, synephrine analogues, ritodrine and dopamine) that show reversal of β 2 -/β 1 -AR efficacy profiles, thus producing considerable levels of receptor-arrestin complex via β 1 -AR, but undetectable levels via β 2 -AR. As demonstrated for dobutamine, these ligands are competitive antagonists of the β 2 -AR-arrestin interaction induced by a full agonist. The dobutamine K i value for blocking adrenaline on β 2 -AR-arrestin is very close to its EC 50 as an agonist on the β 2 -AR-G-protein interaction. Thus the loss of β 2 -AR efficacy on arrestin is not due to reduced binding affinity for the β 2 -AR-arrestin complex. The most logical conclusion is that these ligands are capable of inducing a proper 'arrestin-fitting' conformation of the receptor when binding to the β 1 -AR subtype, but fail to do so when occupying the site of the β 2 -AR subtype.
Although data derived from the direct measurement of proteinprotein association are the best to gauge the conformational change that each ligand structure can transfer to the receptortransducer interface, they cannot predict the relative effect of such a change on downstream signalling. In fact, a complex signalling network can generate strong non-linearity between receptortransducer complex formation and resulting biological responses. Thus the profile of β 1 -/β 2 -AR selectivity that we have seen in the present study at the molecular level might be considerably altered at the stage of arrestin-mediated functional responses.
With such a caveat in mind it is, however, interesting to note that dobutamine and dopamine are clinically relevant sympathomimetics, considered to exert β 1 -AR-mediated inotropic effects via cAMP signalling. Yet we find that the transducer where such drugs show β 1 -AR selectivity of efficacy is arrestin, not G s . This suggests a role for arrestin in mediating adrenergic control of the myocardial contractile response. Indeed, a recent study has demonstrated that arrestins can mediate enhancement of cardiomyocyte contractility via angiotensin 1 receptors [40] , and rapid changes of local free Ca 2 + , apparently mediated by β-arrestin-2/ERK (extracellular-signal-regulated kinase) via β 2 -AR, were described in hippocampal neurons [32] . The efficacy profile of 'dobutamine-like' agonists identified in the present study predicts a peculiar pattern of receptor-transducer output in cells expressing both β 1 -ARs and β 2 -ARs; G-protein responses are activated via both subtypes, but arrestin signalling can only occur through the β 1 -AR, as these ligands block the influence of endogenous catecholamines on the β 2 -AR-arrestin interaction. One obvious question is whether such an imbalance in β 1 -/β 2 -AR-mediated signalling might be related to the adverse effects that dobutamine has shown in clinical trials of heart failure patients [41] . Interestingly, a functional distortion in the relative balance of β 1 -/β 2 -AR-mediated signalling, resulting from the loss of compartmentation, was found in myocardiocytes from failing hearts [7] .
In conclusion, we have shown that the β 1 -/β 2 -AR efficacy profiles of adrenergics are diametrically different for G-protein and arrestin. This primarily reflects an inversion in the strength of receptor-transducer interactions (β 2 -AR > β 1 -AR for G-proteins and β 1 -AR β 2 -AR for arrestins). We have also identified a group of β 1 -selective arrestin agonists, which can induce formation of the receptor-arrestin complex only when bound to the β 1 subtype.
AUTHOR CONTRIBUTION
Ida Casella, Caterina Ambrosio and Maria Cristina Grò conducted the experiments. Paola Molinari, Ida Casella and Maria Cristina Grò prepared the chimaeric constructs and transfected cell lines used in the present study. All authors contributed to the experimental design, data analysis and preparation of the paper, which was written by Ida Casella and Tommaso Costa. Intrinsic activities (as relative E max values) of the agonists at the indicated concentrations were measured in two different cell lines. Direct BRET between luminescent β 2 -AR and fluorescent arrestin was measured in the 2B2 G s -KO cell line used to generate the data for arrestin coupling in the present study (open bars). Indirect BRET (generated by molecular clustering between an mtRGFP reporter of endocytosis [1] and 'dark' β 2 -AR bound to luminescent arrestin) was measured in a HEK-293 line co-expressing mtRGFP and Rluc-β-arrestin 2, and additionally transduced with a puromycin-resistant construct coding for wild-type β 2 -AR (closed bars). BRET recording was done as described in the main text, except that coelenterazine was used as substrate in HEK-293 cells. The 'net' BRET signal after subtraction of basal signal recorded in the presence of adrenaline was 9.3 + − 0.88 in the direct assay and 2.1 + − 0.1 in the indirect assay respectively. Note that in the indirect assay the receptor bears an intact C-terminus. Data are means + − S.E.M., n = 4; S.E.M. values were calculated from the sum-of-variances observed in the presence and absence of ligands. wt, wild-type. Table. The solid line is computed by linear regression of the data, which yielded a slope not significantly different from unity (t test). Dashed lines were computed from + − 1 standard error of the slope.
Figure S3 Effect of changes in receptor/G β stoichiometry of expression on the determination of ligand intrinsic activities
Cell lines named β1 and β2 are multiclonal HEK-293 lines obtained by transducing a stable line expressing RGFP-G β1 with viral constructs coding for luminescent β 1 -or β 2 -ARs, and selected with G418 plus hygromycin antibiotics. Cells indicated as B and C are clones obtained by viral transduction of the same master RGFP-G β1 line, except that, after the infection, cells were replated at low density, selected with proper antibiotics for 2-3 weeks and isolated using cloning rings. Line β2-B(αs) was generated by additionally infecting clone β2-B with a viral contruct encoding the G αsL sequence and selected for puromycin resistance. The intrinsic fluorescence and luminescence of the membranes was calculated by linear regression using four to five serial dilutions of membrane proteins and the data are shown (A and C) as fraction of the values measured in multiclonal lines β1 and β2 using a log10 scale. Line A is the stable 2B2 cell line expressing β 2 -AR-Rluc and RGFP-β-arrestin 2 which was used for the pharmacological comparisons in the present study because its levels of fluorescence and luminescence expression are identical with those of a similar line expressing the β 1 subtype. Line B is an independent β 2 -AR-expressing cell line which has similar fluorescence expression (A/B ratio = 0.96 + − 0.38, n = 3), but a greater level of luminescent receptor (A/B ratio = 2.48 + − 0.29, n = 3). Top panels: concentration-response curves for enhancement of the RET ratio using the ligands indicated in the boxed legend, drawn with the corresponding best-fitting curves (solid lines). Data were fitted to a general logistic function as reported in the Experimental section of the main text. Bottom panel: the E max computed in the cells with higher receptor expression are plotted as a funtion of the corresponding E max values computed in the cells with lower receptor expression. The dashed line shows the identity relation, which would describe the data if the intrinsic activities in the two cells were superposable. Note that the increase of receptor at constant tranducer expression causes a significant reduction in RET ratio, but only a slight distortion in the intrinsic activity of partial agonists, as it can be predicted by theoretical analysis of receptor-tranducer interactions (see the section "Analysis of ligand-induced receptor activation using RET methods" in the Supplementary material). This pattern is consistent with a level of receptor expresssion in line A which is below the level of transducer expression.
Table S1
Structures, intrinsic activities and EC50 of all ligands used in the present study IA, intrinsic activity, calculated as (E max (ligand) -basal) / (E max (epi) -basal), both for assays made using single saturating concentrations and for concentration response (CR) curves; Err, indicates the mean standard error (for n >2) or the range of the two measurements; A, Sigma-Aldrich; B, Tocris; C, Gift of Professor Ad Ijzerman. 
ANALYSIS OF LIGAND-INDUCED RECEPTOR ACTIVATION USING RET METHODS
Relationship between molecular efficacy and intrinsic activity of ligands
The RET signals measured in the present study report the formation of a complex between a donor linked to a receptor and an acceptor fused to a transduction protein in response to ligand binding to the receptor. The simplest model to describe such an interaction (assuming that the affinity between donor and acceptor is negligible compared with those of the reported proteins) is delineated by either one of the two reaction cycles drawn below:
where R d and a Y are the donor-linked receptor and acceptorlinked transduction protein, while X is the ligand binding to R d . The symbols Δ X and Δ Y represent free energy changes for the two interactions leading to bimolecular complexes. The only difference beteween 1a and 1b is that the species carrying the donor-acceptor complex da (i.e. R da Y and XR da Y) are in the first model formed by the transducer association with the receptor (e.g. receptor-arrestin binding), whereas, in the second model, result from the intramolecular rearrangement of a prebound receptortransducer complex, R d a Y → R da Y, (as might be the case for receptor-G-protein subunit interactions). Thus the reaction driven by Δ Y is bimolecular in 1a and monomolecular in 1b, but the behaviour of the two systems is otherwise very similar. In both models the quantity δ xy (i.e. the net free energy difference between vertical and horizontal reactions) is the coupling free energy of the system [2] [3] [4] , which measures the interdependence between X and Y interactions with the separate contact sites on R d . If δ xy = 0 there is no linkage, but δ xy <0 or δ xy >0 imply that the binding of ligand X enhances or diminishes the binding (or the rearrangement process) between a Y and R d (noting that a Y reciprocally exerts identical effects on the binding of X). Thus δ xy quantifies the molecular efficacy of any ligand X to drive the interaction beween receptor R and transducer Y [5, 6] .
In a BRET system, the signal reporting the change of interaction between receptor and transducer is generated by the change of the ratio of intensity between resonant and non-resonant emissions. This reflects the proportion of species that carry the donoracceptor complex and those containing only donor. Thus we can define a theoretical response of the system two ratios of signalgenerating species (SG r ): in 1a, the fraction between receptors coupled and uncoupled to the transduction protein Y, in 1b, the ratio between rearranged and resting receptor-transducer complexes:
To visualize the dependence of SG r on the concentration of X, models 1a and 1b can be solved numerically given any arbitrary value of reactant concentrations and the equilibrium constants related to the free energy changes x , y and δ xy (see details under the 'Computations' section below). Figure S5 (A) shows how the concentrations of species carrying the light emitting forms da and d (for 1a), or da and d a (for 1b), and the corresponding ratios, change with increasing ligand X. Note that the EC 50 of the SG r response is displaced rightwards compared with that for the formation of the ligand-bound dacarrying complex. Figure S5 (B) depicts the relationship between ligand intrinsic activity (expressed as the maximal change of SG ratio relative to the ligand with the greatest efficacy) and different values of molecular efficacy α.
Using the mass-action law equations shown in the 'Computations' section and the definitions of SG r given above, we can derive the following equations relating ratios of signalgenerating complexes and molecular efficacy α:
As the value of X gets larger, such relations can be simplified as follows:
Thus model 1b predicts a linear relationship between the maximal enhancement of X-induced SG r and molecular efficacy, with a slope constant that corresponds to the intrinsic equilibrium of the receptor-transducer complex K y . However, in model 1a the relationship is more complex because the concentration of free transducer [
a Y] varies with the value of α, to an extent reflecting the magnitude of K y and the stoichiometric relationship between total R d and a Y. This is shown in Figure S6 , where maximal displacements of SG ratios are computed according to model 1a for various values of the parameters and equilibrium constants. It is clear that the relationship is fairly linear as long as the receptor concentration is below that of the transducer, but becomes hyperbolic to a degree dependent on receptor-transducer affinity when the concentration of total receptor matches or exceeds the concentration of total tranducer.
Ratio of signal-generating species and experimentally measurable BRET ratios
It is far more useful to analyse how the theoretical change of SG ratios may be related to the change of RET ratios detected in experiments. In a BRET system such a change is measured as the ratio of light intensity between the low-energy radiation emitted via the donor-acceptor complex da and the high-energy radiation emitted from the uncoupled donor d. If, and only if, the transfer of resonance energy in the da complex was perfectly efficient, lower energy photons would solely come from the dacontaining species and higher energy photons from d bearing species, thus BRET ratios would change proportionally to the change of SG ratios as illustrated above. However, the RET efficiency in the da complex is generally not even close to the theoretical maximum. Thus a significant fraction of photons in the high-energy channel is contributed by species that carry the da complex.
Therefore, to visualize the change of BRET ratios according to the models, we need to consider the RET efficiency of the da complex. Since BRET experiments are always based on the ratiometric measurement of spectrally resolved luminescence, we can pragmatically define an efficiency parameter, e, as the fraction of photons in the low-energy channel over the total (high + low energy channel emissions) detected for any given da complex.
The underlying assumption in the treatment that follows is that experimental BRET ratios are corrected for spectral overlap. That is, the higher-energy light component coming from the lowenergy acceptor emission and the lower-energy component of donor emission can be measured and subtracted from the data prior to the computation of BRET ratio. Thus low-energy emission is proportional to the concentration of da complexes that emit the resonant light with efficiency e, whereas the higher-energy emission represents the sum of free donor d plus the fraction of da complex that emits through the donor part of the complex with efficiency 1 − e.
Then in model 1a the experimental RET ratio can be defined as:
RET ratio (in 1a) = low-energy channel emission high-energy channel emission
and the relationship between maximal change of RET ratio and molecular efficacy α is:
Evidently, even a small variation from unity of the efficiency factor e can cause a significant discrepancy between the true distribution of signal-generating species (see eqn 1.1) and the corresponding change of the experimentally observable BRET ratio.
In model 1b there would be a similar relationship only if in the 'resting' transducer-receptor complex (R d a Y), donor and acceptor are so far apart that no RET emission can possibly occur. However, the more realistic scenario is that both the initial ( RET ratio (in 1b) = low-energy channel emission high-energy channel emission = e 1 S + e 2 T (1 − e 1 ) S + (1 − e 2 ) T and the relationship between maximal X-induced RET ratio and α is: max RET ratio(X →∞) ≈ e 1 + α K y e 2 1 − e 1 + α K y (1 − e 2 ) eqn 2.2
Unless e 2 is exactly equals 1 (in which case eqn 2.2 predicts a linear relationship between max RET ratio and α, with slope/intercept ratio = K y /e 1 ), it is obvious that the experimentally observable maximal ligand effect on the BRET ratio is not linearly related to molecular efficacy of the ligand. In other words, even if this model would in principle predict a linear correspondence between maximal change of receptor-tranducer complex and ligand efficacy (eqn 1.2), the discrepancy between molecular changes and the detectable optical signal makes such a relationship non-linear. Figure S7 shows the discrepancy between BRET ratios and true change of receptor-transducer interactions for different efficiency values, as predicted by either model 1a or 1b. To facilitate a direct comparison, the same parameters previously employed in Figure  S5 were used to generate the data of Figure S7 .
For model 1a the change in distribution of free and tranducerbound receptor species induced by X (solid lines) significantly differs from the change in distribution of light emissions observable as BRET ratio (symbols), and the discrepancy gets larger the smaller the efficiency factor e ( Figure S7 , top panels). Note that the ligand EC 50 (potency) for the enhancement of the RET ratio differs from the EC 50 for increasing SG ratios, and becomes closer to the EC 50 for the formation of the receptortranducer complex as the efficiency of the da complex diminishes. The same trend is true for model 1b ( Figure S7 , bottom panels) where the ligand EC 50 for the change of the RET ratio is much smaller than that for the change of the SG ratio, under diverse conditions of e 1 , e 2 values and their differences.
Figures S8-S10 show some examples of how the efficiency of the donor-acceptor complex can influence the relationship between maximal ligand effect on BRET ratios and molecular efficacy, and how such a relationship depends on the value of K y . Simulations according to model 1a are in Figures S8 and S9 , whereas those based on model 1b are reported in Figure S10 .
According to model 1a, as long as the value of K y is not too large, the increase in stoichiometrical ratio between total receptor and total transducer concentrations decreases maximal ligand effects on BRET ratios. This effect is greater at higher levels of efficiency in the donor-acceptor complex ( Figure S8 , top panels). However, the relative intrinsic activity of ligands computed thereof are minimally affected until receptors do not exceed the transducer concentration, both for high and low efficiency values ( Figure S8 , bottom panels).
In contrast, even for receptor/transducer ratios below unity, increasing the affinity K y that controls the interaction between receptor and transducer can alter the intrinsic activity of ligands derived from BRET ratios, and the effect of K y depends on the efficacy of the da complex. This is illustrated in Figure S9 , where the intrinsic activities of a group of ligands having a fixed range of molecular efficacies are measured for a reference receptor 1 and are compared with those for receptors with different values of transducer affinity. The greater the change in K y , the more hyperbolic becomes the relationships of intrinsic activities among the compared receptors, and this effect is amplified at a smaller RET efficiency ( Figure S9 ).
This dependency of ligand intrinsic activities on K y is even more striking for model 1b, as shown in Figure S10 .
A plot similar to that of Figure S9 , but generated according to model 1b is shown in Figure S10 , where the intrinsic activities of a set of ligands with a fixed range of efficacy are compared on RY complexes that have various values of the stability constant K y . The relationships are hyperbolic, and the deviation from linearity increases as the difference in equilibrium constant rises. Note that the shape of the relationship is not particularly affected by the values of e 1 and e 2 . Receptor species are plotted as fractions of total R (or total RY in 1b). Note that SG ratios are scaled by different factors in order to show them on similar y axes. (B) SG ratios were computed for ligands with different values of α (as labelled) using parameters identical with those of (A) and were converted into intrinsic activity by dividing all data for the maximal change of SG r induced by the X with the highest a value. The X binding affinity K x is maintained equal for all curves. Parameters are as used in Figure S8 , maintaining a receptor/transducer ratio fixed at 0.6. The intrinsic activity measured at a reference receptor 1 (K y = 2 × 10 8 M − 1 ) on the x axis is compared with those computed for smaller or greater values of K y as indicated in the legend. Data are computed according to model 1a, using the efficiency values shown on the top of the plots.
